|
India’s research ecosystem is increasingly focusing on the convergence of pharmaceuticals and nutraceuticals as a strategic approach to address the growing burden of metabolic disorders such as diabetes, obesity, and cardiovascular diseases.
Researchers are exploring how evidence-based nutraceutical interventions ranging from bioactive compounds to functional foods can complement conventional pharmaceutical therapies to improve prevention, treatment outcomes, and long-term disease management. This integrated model is gaining momentum as it aligns with the need for more holistic, cost-effective, and patient-centric healthcare solutions.
Commenting on how nutraceuticals activate GLP-1 pathways effectively, Dr Arunkanth Krishnakumar, co-founder and CEO, Zeus Hygia Lifesciences, said glucagon-like peptide1 (GLP-1) has emerged as a key target in metabolic disease management due to its role in glucose regulation, appetite control, and energy balance. As an incretin hormone, it enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, contributing to improved glycaemic control and weight modulation.
While GLP-1 receptor agonists have demonstrated strong clinical efficacy, nutraceuticals are being explored in this context for their ability to influence metabolic pathways through gut-mediated and cellular mechanisms, he added.
Bioactive compounds such as polyphenols, berberine, dietary fibres, and probiotics have shown potential to indirectly support GLP-1 secretion. However, the extent of GLP-1 activation through nutraceuticals remains modest compared to pharmacological interventions. As a result, their relevance lies primarily in early-stage metabolic dysfunction, preventive care, and as adjuncts to established therapies. Current research is focused on improving bioavailability, formulation, and clinical validation to ensure more consistent outcomes. As evidence strengthens, nutraceuticals may play a defined supportive role in modulating GLP-1 pathways within integrated metabolic care models, Dr Krishnakumar told Pharmabiz.
The management of metabolic disorders is evolving toward more integrated and patient-centric models. While pharmaceuticals have long been the cornerstone of treatment due to their targeted efficacy, their limitations in long-term prevention and accessibility have become increasingly evident, he said.
Therapies such as GLP-1 receptor agonists have delivered significant clinical benefits in glycaemic control and weight management. However, cost considerations, potential side effects, and adherence challenges continue to influence their adoption, particularly in emerging markets.
Nutraceuticals, in parallel, are gaining traction for their role in supporting metabolic health through multi-pathway mechanisms. Compounds including berberine, omega-3 fatty acids, probiotics, and dietary fibres contribute to improved insulin sensitivity, lipid metabolism, and inflammation control. These effects are often mediated through metabolic regulators and gut microbiome interactions.
The opportunity lies in convergence rather than substitution. Nutraceuticals can complement pharmaceutical interventions by supporting early intervention, enhancing metabolic resilience, and contributing to long-term disease management strategies. Advances in formulation science, clinical research, and standardization are enabling nutraceuticals to move closer to evidence-based healthcare solutions. As this integration deepens, a more cohesive approach is emerging, one that bridges prevention and treatment, and supports a continuum of care in metabolic health, said Dr Krishnakumar.
|